NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Results of Operations and Financial Condition
ITEM2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On May9, 2017, Neurocrine Biosciences, Inc. announced its
financial results for the first quarter ended March31, 2017. The
full text of the press release issued in connection with the
announcement is attached as Exhibit 99.1 to this Current Report
on Form8-K.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act) or otherwise subject to the liability of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a
filing.
ITEM9.01 FINANCIAL STATEMENTS AND EXHIBITS.
| (d) | EXHIBITS. |
|
Exhibit Number |
Description of Exhibit |
|
| 99.1 | Press Release dated May9, 2017 |
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature. NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Recent Trading Information
NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) closed its last trading session up +0.94 at 52.60 with 897,284 shares trading hands.
